Oncology Peer Review On-The-Go: Focus of Current and Emerging Therapies in Follicular Lymphoma

Kirk E. Cahill, MD, and Sonali M. Smith, MD, spoke with CancerNetwork® about their review of the current management and treatment of follicular lymphoma published in the journal ONCOLOGY®.

Kirk E. Cahill, MD, and Sonali M. Smith, MD, both of the Department of Medicine, Section of Hematology/Oncology at the University of Chicago Medicine Comprehensive Cancer Center in Chicago, Illinois, spoke about their manuscript titled, ‘Follicular Lymphoma: a Focus on Current and Emerging Therapies,’ that was recently published in the journal ONCOLOGY®.

In the review, the authors explore current approaches to the diagnosis and treatment of follicular lymphoma, with a focus on emerging investigational therapies and novel combination strategies. Some areas of unmet need they touch on in the paper include precision approaches to individual patients, trial end points with quality-of-life measures, and guidance for sequencing of available regimens and agents.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.
An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.
An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.
Expert on FL
Expert on FL
Experts on FL
Related Content